June 17th 2026
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.
June 8th 2026
FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.
March 10th 2026
Global biosimilar market shifts: Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.
March 9th 2026
Biologics eat 51% of drug spending despite being 5% of prescriptions, but the FDA's new draft guidance hopes more competition can close that gap.
January 12th 2026
ACP Calls for Biologics Marketplace Reforms
The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace.
Merck's Etanercept Gains More Indications for Use in Canada
A broader range of indications in rheumatology combined with a Canadian push for biosimilar acceptance bodes well for Merck's Brenzys product.
Rep Grothman Introduces Bill for Automatic Insulin Biosimilar Interchangeablity
Representative Glenn Grothman, R-Wisconsin, says interchangeability for insulins makes sense based on the savings potential and safety record of these agents.
What We Learned About Biologics on Summer Vacation
Intellectual property law attorneys from the Washington, DC, offices of McDermott Will & Emery LLP, discuss 5 of the most significant trends in biologics litigation that have emerged in recent months.
FDA Draft Study on Biosimilar Disclosures Draws Fire
Trade associations and companies in the biosimilars business ask the FDA to hone its proposed study on product disclosures.
Study Suggests Biosimilar Suffixes Influence Patient Willingness to Switch
The random jumble of letters that the FDA attaches to new biologics and biosimilars plays a big role in patient acceptance of these drugs, investigators report.
Biosimilarity: A Novel Approach to Develop Therapies and Vaccines for COVID-19
Bio-Thera Begins Phase 1 Trial for Ustekinumab Biosimilar
Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
Samsung Bioepis Exec Discusses European On-Ramp for Aybintio
Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.
Report: PBM "Reforms" Leave Biosimilars Out in the Cold
It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.
Biocon, Mylan Launch Semglee and Seek Biosimilar, Interchangeable Status
For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.
The Pandemic's Multilevel Effect on Patient Access
Coronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.
Dan Leonard Takes Helm of Association for Accessible Medicines
The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, chose a leader with a research, public relations, and strategic planning background.
Expert Opinion Roundup: New Insulin and Biosimilar Regulation
Opinion leaders discuss the significance of regulatory changes affecting biosimilar and insulin products.
Biogen: Anti-TNF Biosimilars Are Underutilized
Two Biogen officials make the case for getting anti–tumor necrosis factor (TNF) biosimilars into wider play.
BeiGene, Bio-Thera Carve Out Bevacizumab Market
From China to Taiwan, BeiGene and Bio-Thera Solutions hope to capture a large share of the bevacizumab biosimilar market.
Formycon, Bioeq Enroll First Patient in Phase 3 Aflibercept Study
Multiple contenders are lining up for the pending expiration of patents on the blockbuster Regeneron reference product for wet age-related macular degeneration.
FDA Reassures on Biosimilar Progress as COVID-19 Applications Pile Up
The buck stops with the FDA when it comes to approving coronavirus disease 2019 therapeutics applications, said Anand Shah, MD, deputy commissioner for Medical and Scientific Affairs at the FDA.
Samsung Bioepis' Bevacizumab Is Cleared for Launch in Europe
Samsung Bioepis' latest approval gives it 5 biosimilar approvals in the European marketplace.
Sandoz Canada Launches Ziextenzo, Riximyo
After receiving regulatory approval in June, Sandoz launched 2 of its biosimilars on the Canadian market.
Fauci Discusses Experimental COVID-19 Drugs and School Openings
Monoclonal antibodies may play a frontline role in dealing with COVID-19 infections, according to Anthony S. Fauci, MD.
US May Need to Look to Germany to Reform Drug Pricing
US administrative and legislative efforts are moving the United States and Germany more into alignment on drug cost management philosophy, according to a review.
Winegarden: Biosimilars Market Lacks Oomph
A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .
Irish Pharmacists Lobby for Biosimilar Substitution
Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings owing to the absence of a biosimilar substitution policy.
Biosimilars Gain Market Share and Advocates Get Aboard
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
China Approves Henlius' Biosimilar Trastuzumab
Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.
Celltrion Refutes Critique of CT-P13 Equivalence
Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.
Pfizer Expert Urges Employers to Get Proactive on Biosimilars
Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.
Christine Simmon and the Fight for Patent Reform
Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.
USP Panel Recommends Quality Upgrade for India's Biopharmaceutical Industry
United States Pharmacopeia (USP), the FDA, and others deliver constructive critique on how India can bolster quality in its biopharmaceutical industry.